4D Molecular Therapeutics to present interim 4D-150 wet AMD data at September 2024 medical conference

4D Molecular Therapeutics, Inc.

Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.
Specific forum and date to be disclosed with Q2 2024 financial results in August 2024.
52-week landmark analyses for Dose Expansion and Population Expansion cohorts on track for February 2025 as previously disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.